Mark Caulfield is Director or the William Harvey Research Institute at Barts and the London. He has co-ordinated the multicentre MRC British Genetics of Hypertension (BRIGHT) Study since 1996 which has established the largest carefully characterised hypertensive family resource and matched controls in the World. Mark Caulfield has combined this with a strong engagement in cardiovascular clinical trials, notably the Anglo-Scandinavian Cardiac Outcomes Trial. This has provided important data showing that blood pressure lowering with newer antihypertensives is superior to older therapies in terms of reducing mortality and morbidity from cardiovascular disease. In association with this trial he has led establishment of a major genetic repository which can be used to evaluate candidate genes for hypertension and the pharmacogenetic response to treatments. In 2002 he became Director of the William Harvey Research Institute and has established a successful genome centre which underpins 40 research programmes about 25% of which are external to his University.